Anacor Pharmaceuticals Announces That It Has Submitted a New Drug Application to the FDA for Tavaborole

  Anacor Pharmaceuticals Announces That It Has Submitted a New Drug
  Application to the FDA for Tavaborole

Business Wire

PALO ALTO, Calif. -- July 29, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that on July 26, 2013 it
submitted its New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) for tavaborole, its drug candidate for the topical
treatment of onychomycosis. Onychomycosis is a fungal infection of the nail
and nail bed that affects approximately 35 million people in the United

“The submission of the NDA is a significant milestone for Anacor,” said David
Perry, Anacor’s Chief Executive Officer. “Anacor was founded eleven years ago
based on the promise of boron chemistry. Tavaborole is the first drug in our
pipeline to reach this important milestone, and I’d like to acknowledge and
thank the entire Anacor team for their hard work, dedication and persistence.”

Anacor announced earlier this year that tavaborole achieved statistically
significant and clinically meaningful results on all primary and secondary
endpoints in two Phase 3 pivotal studies of tavaborole to treat onychomycosis
topically without concomitant debridement. The only currently FDA-approved
topical treatment for onychomycosis is approved with concomitant nail
debridement, and currently approved oral therapies have been associated with
rare but serious safety issues.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 an antibiotic for the treatment of infections
caused by Gram-negative bacteria. We have discovered three other compounds
that we have out-licensed for further development — two compounds for the
treatment of animal health indications that are licensed to Eli Lilly and
Company and AN5568, also referred to as SCYX-7158, for human African
trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for
Neglected Diseases initiative, or DNDi. We also have a pipeline of other
internally discovered topical and systemic boron-based compounds in
development. For more information, visit

Forward-Looking Statements

This press release may contain forward-looking statements that relate to
future events including the FDA’s acceptance of Anacor’s new drug application,
or NDA, related to tavaborole and the potential FDAapproval of tavaborole.
These forward looking statements involve known and unknown risks,
uncertainties and other factors that could cause actual levels of activity,
performance or achievement to differ materially from those expressed or
implied by these forward-looking statements, including risks related to
regulatory approval of new drug candidates. Reference should be made to
Anacor's Annual Report on Form 10-K for the year endedDecember 31, 2012,
filed with theSecurities and Exchange Commissionunder the heading "Risk
Factors" and Anacor's subsequent Quarterly Reports on Form 10-Q for a more
detailed description of such factors. These statements reflect the views of
Anacor as of the date of this press release with respect to future events and,
except as required by law, it undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this press release.


Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.